


Glucocorticoids

Histology of the adrenal cortex

Three concentric zones comprise 80-90%





Zona glomerulosa

Zona fasciculata

Zona reticularis



Zona glomerulosa (outer zone)

producing mineralcorticoids (aldosterone)



Zona fasciculata (middle zone)



producing glucocorticoids (cortisol)





Zona reticularis (inner zone)

producing sex steroids

(dehydroepiandrosterone (DHEA) : androgens)








Mechanism of glucocorticoid action on cellular level

After entering the cell they bind to specific receptors in cytoplasm causing change of conformation = activation of receptors

Complexes of corticoid + receptor are transported to cell nucleus and bind to DNA elements.

The result is increased transcription of genes either inducing or inhibiting synthesis of other proteins

- GLC receptors are present in all tissues!!!
- Proteins called **lipocortins** are able to suppress phospholipase A




Endogenous secretion:

Quiescent : 25 - 30 mg /24

In stress: 10-fold

Not stored – rate of synth. = rate of release

Maximal: 6-8 A.M.



Pharmacokinetics

- Bound to CBG and albumin
- Intensively metabolised
- Metabolites excreted in 72 h
- Synthetic ones have longer t_{half}
- (prednison – prednisolon)

Physiological effects of Glucocorticoids

- 1. Influences on intermediary metabolism**
- 2. Permissive Action and circulatory effects**
- 3. Effects on Water Metabolism**
- 4. Effects on the bones and muscles**
- 5. Anti-inflammatory, anti-immune effects**
- 6. Effects on the Central Nervous System**
- 7. Developmental effects**

Effects (therapeutic):

- anti-inflammatory
- antialergic and immunosuppressive
- antiproliferative

- Substitution (therapeutic)

Membrane phospholipids

Glucocorticoids

Phospholipase A2

Arachidonic acid

Inh. 5-LOX

lipooxygenase

**A-A
NSAID**

cyclooxygenase

LEUCOTRIENS

PROSTAGLANDINES
PROSTACYCLINES
TROMBOXANES

Mobilization of fagocytosis
Changes in vessels permeability
Inflammation

inflammation

Indications

Physiological doses

substitution – adrenocortical insufficiency, congenital adrenal hyperplasia, Addison disease (*hydrocortisone, fludrocortisone*)

Pharmacological doses

Antiinflammatory and immunosuppressive effects

astma (inhalations)

topic application, in allergy (conjunctivitis, rhinitis)

hypersensitivity in general

anaphylaxis

autoimmune diseases (rheumatoid arthritis, Crohn disease ...)

prevent non-acceptance in transplantations

Indications

Oncology

**Acute Lymphoblastic Leucaemia, hodgkin disease
tumors of brain (antioedematose effect - dexamethasone)
antiemetics**

Others

**height sickness, nephrotic sy., sclerosis
multiplex, subacute thyreoiditis**

Adverse effects (after pharmacological intervention!)

1) ↓ Immune responses

recurrent infections, ulcer disease, mycotic infections...

2) Decrease in endogenous corticoid production (suppression of axis hypothalamus – pituitary – adrenal glands)

--- acute insufficiency in sudden glucocorticoid withdrawal

3) Osteoporosis

4) Mineralocorticoid action – water retention, salts

↑ blood pressure, Na, Cl

↓ K⁺, NO production

Adverse effects (after pharmacological intervenece!)

5) Steroid diabetes mellitus

6) Muscle atrophy

**7) Psychotropic effect: euphoria/
depression/psychosis**

8) ↑ gastric secretion of HCl

**9) Cartilage impairment, striae, reduced wound
healing**

**9) others: increased clotting, ↑ thrombocytes, erys
glaucoma, increased intracranial pressure**

Iatrogenic Cushing sy.

Sudden weight gain

Central obesity

Hypertension

Proximal muscle weakness

Diabetes mellitus

Decreased libido or
impotence

Depression or psychosis

Osteopoenia or osteoporosis

Easy bruising

Hyperlipidemia

Menstrual disorders

Violaceous striae wider
than 1 cm

Recurrent infections

Acne

Hirsutism...




Figure 47-9 Common characteristics of Cushing's syndrome.

Copyright © 2000 by Mosby, Inc.


Glucocorticoids:

	Glucocorticoid effect	Mineralocorticoid effect
Cortisol	1	1
Cortisone	0,8	0,8
Prednisone	4	0,8
Prednisolone	4	0
Triamcinolon	5-10	0
Betametazon	25	0
Dexametazon	25	0

Typically administered glucocorticoids

- hydrocortisone
- dexamethasone
- prednisolone
- triamcinolone
- flumethasone
- prednikarbat
- bethametason valerate
- fluocinolone
- betamethason adipate
- budesonid
- halcinomide
- clobetasole

Weak action



Very strong acting

CAVE !

To prevent axis suppression

(hypothalamus- ant. pituitary – adrenal glands)

- Administration up to 10 days
- 6 - 8 A.M.
- Preparations with lower blocking effect
(non-fluorinated derivatives)
- Pulse therapy

Adverse effects prevention

- lowest effective dose should be administered
- topic administration if possible (inh., rect., intraarticular, s.c.)
with low bioavailability
- total dose can be decreased by combination with immunosuppressives
- dosing schedule should reflect circadian rhythm – if possible (not in life threatening situations)
- avoid sustained release preparations
- stepwise decreasing of doses

approx. 2.5 mg eq. prednisolone /3 days

Contraindications

- hypertension
- heart insufficiency /CHF
- Cushing. sy
- peptic ulcer
- diabetes
- glaucoma
- psychoses
- viral/bacterial infection
- vaccination with attenuated vaccine